CureVac Shares Hit All-Time Low on German Patent Court Ruling
By Dean Seal
Shares of CureVac fell to an all-time low after the company said a German federal court has denied the validity of an intellectual property patent related to messenger ribonucleic acid technology in Covid-19 vaccines.
The stock dropped 41% to a low of $3.41 on Tuesday. Shares have fallen by a third since the start of the year.
The German biopharmaceutical company said the German Federal Patent Court granted a nullity action filed against CureVac's patent by rival BioNTech.
The two competitors are in ongoing patent litigation involving eight CureVac intellectual property rights. Proceedings regarding the seven remaining rights will be decided individually.
CureVac said it will appeal the German court's decision.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 19, 2023 11:57 ET (16:57 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks